Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19.

NCT04471987 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT04471987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04471987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19.
Lead sponsor
Philogen S.p.A.
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2020
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor